Neuren Pharmaceuticals wins Bioshares Excellence Award 🥇 ASX-listed AusBiotech member Neuren Pharmaceuticals (ASX:NEU) swoops up Blake Award for Excellence after a knock-out year including an FDA approval and key commercial partnerships. ausbiotech.org/news/neuren-ph…

AusBiotech responds to research funds consultation, stating process must not overtake purpose behind funds, in response to consultation paper Improving alignment and coordination between the MRFFF and NHMRC’s Medical Research Endowment Account (MREA). ausbiotech.org/news/ausbiotec…

New AusBiotech report shows increasing US investment in Australian biotechs 📈 Australia continues to attract significant investment from US investors, with US investment into Australian life science companies totaling US1.43 billion between 2018-2022. shorturl.at/tGL78

.Immutep receives positive scientific advice from the European Medicines Agency #AusBioNSW biotechdispatch.com.au/news/immutep-r…

.Peter Mac Cancer Centre selects BindiMaps to launch Victoria’s first hospital ‘Google Maps for indoors’ biotechdispatch.com.au/news/peter-mac…

Our Chair Hon Hon. Jaala Pulford will be leading our mission to the The MedTech Conference in Anaheim, USA – join us for a top level visit program and build international connections! ▶️bit.ly/3rIQKa5

.Dimerix announces successful completion of second DSMB review of ACTION3 trial biotechdispatch.com.au/news/dimerix-a…

AusBiotech weighs in on Industry Growth Program consultation 📃 AusBiotech urges Federal Government to take biotechnology industry’s unique characteristics into account when designing $392.4 million Industry Growth Program. ausbiotech.org/news/ausbiotec…

AusBiotech is proud to launch ‘A Practical Guide to ESG for Australian Life Sciences Companies’ (the Guide) as a pragmatic and easy-to-use #ESG tool for biotechs. Thank you to InnovationAus for profiling this important industry resource. innovationaus.com/industry-first…

.@QIMRBerghofer's Australian vaccine breakthrough offers hope against EBV-associated cancers and MS biotechdispatch.com.au/news/australia…

.Clarity Pharmaceuticals’s theranostic prostate cancer trial advances to highest dose level biotechdispatch.com.au/news/claritys-…

.Merck ANZ partners to pilot the first DeadlyLabs kit biotechdispatch.com.au/news/merck-par…

AusBiotech launches world-first ESG Guide for biotech SMEs AusBiotech’s landmark A Practical Guide to ESG for Australian Life Sciences Companies is launched to help SMEs attract investment and navigate environmental, social and governance (#ESG) reporting. ausbiotech.org/news/ausbiotec…

A major day for Moderna as the company builds its Australian presence biotechdispatch.com.au/news/a-major-d…

.CSL reports strong profit growth with record plasma collections biotechdispatch.com.au/news/csl-repor…

📣AusBiotech 2023 Millis Orator announced Distinguished Australian scientist Emeritus Professor Ian Frazer AC (Ian Frazer) will deliver the Millis Oration at the #AusBiotech2023 national conference in Brisbane. Find out more here: ausbiotech.org/news/ausbiotec…

.Chimeric Therapeutics ASX: CHM reports positive in-vitro data for CHM 0301 next-generation cell platform biotechdispatch.com.au/news/chimeric-…

.ANDHealth and Brandon BioCatalyst's CUREator+ delivers funding boost to commercially focused BioMedTech startups biotechdispatch.com.au/news/cureator-…

.Imugene | Cancer Immunotherapies licenses allogeneic CAR-T with a potential registration study in 2024 #AusBioNSW biotechdispatch.com.au/news/imugene-l…

A leader in biotech valuation, Dr Patrik Frei (Venture Valuation) will deliver an exclusive training workshop, “Biotech-Pharma Product and Company Valuation – an introduction”, as part of #AusBio2023 pre-conference activities in Brisbane. Register today > ausbiotechnc.org/workshops